Apellis Pharmaceuticals Announces Closing of its Initial Public Offering
November 13, 2017
Crestwood, Kentucky, Nov. 13, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through